XML 14 R4.htm IDEA: XBRL DOCUMENT v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Total income and other revenues $ 630,576 $ 568,247
Operating (income)/expense    
Provision for changes in expected cash flows from financial royalty assets (197,485) (127,140)
Provision for credit losses on unfunded commitments (3,700) 0
Research and development funding expense 39,790 50,500
General and administrative expenses (includes $122,292 and $703 of share-based compensation expense for the three months ended March 31, 2026 and 2025, respectively; see Note 4) 159,490 110,705
Financial royalty asset impairment 69,443 0
Total operating expense, net 67,538 34,065
Operating income 563,038 534,182
Other (income)/expense    
Equity in earnings of equity method investees (21,758) (6,443)
Interest expense 93,722 65,261
Losses on equity securities 20,166 45,878
Losses on available for sale debt securities 6,680 3,281
Interest income (6,229) (11,290)
Other non-operating expenses, net 2,201 3,062
Total other expense, net 94,782 99,749
Consolidated net income before tax 468,256 434,433
Income tax expense 0 0
Consolidated net income 468,256 434,433
Net income attributable to non-controlling interests 173,566 195,084
Net income attributable to Royalty Pharma plc $ 294,690 $ 239,349
Earnings per Class A ordinary share:    
Basic (in dollars per share) $ 0.67 $ 0.55
Diluted (in dollars per share) $ 0.67 $ 0.55
Weighted average Class A ordinary shares outstanding:    
Basic (in shares) 436,790 435,480
Diluted (in shares) 556,837 578,102
Income from financial royalty assets    
Total income and other revenues $ 594,992 $ 539,490
Other royalty income and revenues    
Total income and other revenues $ 35,584 $ 28,757